tiprankstipranks
Trending News
More News >
Saniona AB (DE:30S)
:30S
Advertisement

Saniona AB (30S) Price & Analysis

Compare
2 Followers

30S Stock Chart & Stats


Financials

30S FAQ

What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was €0.21 and its highest was €1.01 in the past 12 months.
    What is Saniona AB’s market cap?
    Saniona AB’s market cap is €107.89M.
      When is Saniona AB’s upcoming earnings report date?
      Saniona AB’s upcoming earnings report date is Aug 28, 2025 which is in 37 days.
        How were Saniona AB’s earnings last quarter?
        Currently, no data Available
        Is Saniona AB overvalued?
        According to Wall Street analysts Saniona AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Saniona AB pay dividends?
          Saniona AB pays a Notavailable dividend of €0.009 which represents an annual dividend yield of N/A. See more information on Saniona AB dividends here
            What is Saniona AB’s EPS estimate?
            Saniona AB’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Saniona AB have?
            Saniona AB has 138,030,140 shares outstanding.
              What happened to Saniona AB’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of Saniona AB?
              Currently, no hedge funds are holding shares in DE:30S

              Company Description

              Saniona AB

              Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
              Similar Stocks
              Company
              Price & Change
              Follow
              SynAct Pharma AB
              Xbrane Biopharma AB
              IRLAB Therapeutics AB Class A
              Guard Therapeutics International AB
              Xspray Pharma AB
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis